REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. The Companyâs NAV Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. The Companyâs mission is to transform the lives of patients suffering from severe diseases with significant unmet medical needs by developing and commercializing in vivo gene therapy products based on the Companyâs NAV Technology Platform. The Company seeks to accomplish this mission through a combination of internal development efforts and the efforts of the Companyâs third-party licensees. Source
No articles found.
Misonix, Inc. (Nasdaq: MSON) designs, develops, manufactures and markets ultrasoni...
Misonix, Inc. (Nasdaq: MSON) designs, develops,...
Cortexyme is a biopharmaceutical company developing therapeutics based on data sup...
Cortexyme is a biopharmaceutical company develo...
Rocket Pharmaceuticals, Inc. is an emerging, clinical-stage biotechnology company ...
Rocket Pharmaceuticals, Inc. is an emerging, cl...
Hypertension Diagnostics designs, develops, manufactures, and markets proprietary...
Hypertension Diagnostics designs, develops, ma...
LivaNova is a global medical technology company built on decades of experience and...
LivaNova is a global medical technology company...
Amarillo Biosciences, Inc. develops biologics for the treatment of human and anima...
Amarillo Biosciences, Inc. develops biologics f...
Sangamo Therapeutics, Inc. is focused on translating ground-breaking science into ...
Sangamo Therapeutics, Inc. is focused on transl...
Join the National Investor Network and get the latest information with your interests in mind.